Compare BridgeBio Pharma Inc (BBIO) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs KKR & Co Inc — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while KKR & Co Inc trades at $111.68 (market cap $99.61B). The key difference: KKR & Co Inc is far larger — about 6.1× BridgeBio Pharma Inc's market cap, and KKR & Co Inc pays a 0.7% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | KKR | |
|---|---|---|
Market Cap | $16.36B | $99.61B |
Sector | Health | Financials |
52-Week High | $90.17 | $149.34 |
52-Week Low | $47.29 | $83.88 |
Enterprise Value | $18.14B | $22.17B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
KKR trades at $103.83, up 0.99% with strong bullish momentum. The stock shows robust earnings performance with Q2 2026 EPS of $1.63 beating estimates of $1.43, continuing a trend of positive surprises. Recent acquisitions including Integer Holdings ($4.3B) and Medicover India ($1.39B) demonstrate aggressive growth strategy. Analyst consensus remains overwhelmingly bullish with 24 buy ratings and $127.22 price target, representing 22.5% upside potential from current levels.
KKR presents compelling investment opportunity with strong fundamentals, consistent earnings beats, and strategic acquisitions driving growth. Key risks include integration challenges from recent deals, market volatility affecting asset management fees, and potential regulatory scrutiny of private equity operations. The company's $19.2B infrastructure fund closure signals strong institutional confidence in long-term strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
